

	International Scientific Committee of Ozone Therapy Tel/Fax (+34) 913515175. Cell Phone (+34) 669685429 Avenida Juan Andrés 60. Local 1 – Bajo Izquierdo 28035, Madrid (Spain) info@isco3.org www.isco3.org	SOP: ISCO3/ RES /01/03 Version: 18 ENG Date: 08/02/2021 Page 1 of 5
--	---	--

ISCO3 Clinical Trials Follow-up on the preliminary results about the use of O₂/O₃ in the treatment /prevention of Novel Coronavirus Pneumonia (COVID-19).

Country Region	Protocol	Remarks / Side effects
BAZIL Maria Emilia Gadelha Serra RBR-5v3k5d_emilia.gadelha1@gmail.com	Study of the use of ozone therapy adjunct to the treatment of Covid-19 infections	http://www.ensaiosclinicos.gov.br/rg/RBR-5v3k5d/ Control 150 patients / Treatment 50 Patients (rectal ozone)
Arnoldo de Souza RBR-97nt6j_arnoldos@cardiol.br	Multicentre Study of the Integrative and Complementary Practice of the Use of Ozone Gas in Outpatients with Covid-19	http://www.ensaiosclinicos.gov.br/rg/RBR-97nt6j/ Control 71 patients / Treatment 71 Patients (rectal ozone 30 µg/mL, max 240 mL)
CHINA Hospital / N patients = 4 FINISHED* Reg. ChiCTR2000030102 Researcher: Huiling Huang. / Location: Tianjin Haihe	MAH 100 mL blood + 100 mL, up-to 200 mL, 1-2 times a day. Critical case 2-4 times a day. Time schedule: 10 d Case report in Innovation (N Y). 2020 Nov 25; 1(3): 100060. doi: 10.1016/j.xinn.2020.100060	Patient feels better // Chest tightness is improved ↑ 50 % PaO ₂ after the first application S.E.: Allergy
ChiCTR2000030165 Tianjin University ChiCTR2000030006 Union Hospital	Control group:30; mild ill patients:15; severe/critical ill patients:15;	
CUBA Hosp. Dr. Salvador Allende, Sponsor: Dr. Rodolfo Suárez OZO-001	Rectal insufflation in SARS-CoV2 hosp. patients	↓ Viral Load in 5 days ↑ Clinic
CNIC (Promotor). Inv. P. Zuliyt Zamora R RPCEC00000320	Rectal insufflation in SARS-CoV2 hosp. patients 16 Conventional Therapy / 16 Conventional plus O ₃ rectal (20→40 µg/mL, vol 100 → 200 mL, one every 12 h, total 20 sessions)	Improve clinicals symptoms and oxidative stress markets. ↓ Viral Load in 75% of patients in 6 days.
CNIC (Promotor). Inv. P. Zuliyt Zamora R zuliyt.zamora@cnic.cu RPCEC00000341	Prevalence of positive evolutive PCR in patients with COVID 19 treated with rectal ozone therapy : observational study prospective cohort.	
INDIA Dr Mili Shah CTRI/2020/07/026354	n=60 Rectal insufflation and minor auto haemotherapy together with standard of care. Outcome in: Int Immunopharmacol 2020 Dec 23;91:107301. doi: 10.1016/j.intimp.2020.107301.	There was improved SPO ₂ , clinical symptoms status. There was faster viral eradication from host cells. 77% of subjects from the ozone-treated group were RT-PCR negative on day 5 and 100% subjects were RT-PCR negative on day 10.
CTRI/2020/07/026671	N=10 O ₃ SS Dr Alok Sharma / Dr Mili Arpan / Dr Jignasha	Manuscript on submission
CTRI/2020/08/027038 Dr. Prabhat Kumar / Dr. Ashish	N=100 Study to assess effects of nano ozonised hydrogen peroxide nebulisation on results of RT-PCR for novel corona Virus thus infectivity and clinical course among mild to moderate sick COVID-19 Patients	
IRAN IRCT20191125045492N2 Bagheiat-allah Univ. of Med. Sci. Staff: Dr. Ali Sarrafzadeh/Dr. Izadi/Dr. Effat Nikfarjam	<u>Moderate</u> MAH 100-200 mL O ₃ 1:1 35→45 µg/mL, daily 4 session <u>Severe</u> MAH 200 mL O ₃ 1:1 35 →50 µg/mL daily 7 session O ₃ water 60 mL every 6 h	Preliminary results (n=14): Clinical improve. CT evidence of improvement Not yet recruiting
IRCT20200616047792N1 Behnam heibani behnamshai@gmail.com	Ahvaz University of Medical Sciences	http://en.ircr.ir/trial/48978
IRCT20190618043923N4 NCT04400006	Ozone Autohemotherapy in Covid19.	Tabriz University of Medical Sciences
ITALY ClinicalTrials.gov NCT04366089 N= 152 vs Control. Condition: Mild/Severe Researcher: Fabio Araimo Sponsor: Roberto Poscia M.D., Ph.D.	MAH Proportion of O ₂ /O ₃ : Blood 1:1. 250 mL O ₂ /O ₃ 30 µg/mL, every 12 h for 7 days. Location: Hosp. Umberto I. Roma Approval: Hosp. Umberto I/Univ. Sapienza Roma	Prelim Result in: J Med Virol. 2020 Oct 28. doi: 10.1002/jmv.26636.
Researcher: Amado del Monte / Carlo Tascini ClinicalTrials.gov Identifier: NCT04388514 Z7C2CA5837. Location: Hosp. Univ. Santa M. Misericordia / Udine. EC Univ. Friuli	Proportion of O ₂ /O ₃ : Blood 1:1. MAH 200 mL O ₂ /O ₃ 40 µg/mL, 3 times Groups: Antiretroviral therapy (AT) / or AT + O ₃ N= 90 treated / two groups of 45	Preliminary outcome: Clinical improvement in 35 /36 patients. Inter Emg Med 2020 Nov 1. doi: 10.1007/s11739-020-02542-6
Sponsor: Mariano Franzini // SIOOT Location: 17 Hosp.? N= 73	Mild: MAH blood: 150-200 mL 1:1 O ₃ 30/ 40 µg/mL. 2 times a week. Ozonized oil spray 2 times a day. Moderate: MAH blood: 150-200 mL 1:1 O ₃ 40/ 50 µg/mL. 3 times a week. Ozonized oil spray 2/3 times a day. Ozonized water 250 mL 3 times a day. Severe / Critical: S.E.: 1 death not associated with treatment septic shock	↑: PaO ₂ , clinical symptoms, Renal function, Cardiac frequency, ↓ Fever, ↓PCR, removal of assistant respiration in 5 days. <i>International Immunopharmacology.</i> 2020 August 8, 88: 106879.
SPAIN EudraCT: 2020-002425-28 N= 50 Results available Sponsor: AEPROMO. Approved by etic committee 18/05/2020-05/20	O ₃ SS 5→3 µg/kg b.w. a day x 10 days Vit.C + GSH 1,2 g i.v. in 100 mL Saline ↓ Fever in 3-4 days ↓ Viral Load in 3-4 days	Outcomes in: J Pharm Pharmacogn Res 9(2): 126–142.
ClinicalTrials.gov NCT04359303 N=50 Dr. Javier H. Tallón, Univ. Cat. San A. Murcia	MAH O ₂ /O ₃ : Blood 1:1 200 mL O ₃ 40 µg/mL + Base WHO recommended treatment.	Not yet recruiting
ClinicalTrials.gov NCT04370223 Researcher: Dr. Alberto Hernández N=10 Location: Hosp N. Señora del Rosario. Ibiza	MAH O ₂ /O ₃ : Blood 1:1 200 mL 1:1 O ₃ 40 µg/mL every 12 h for 5 day, 1 session a day up to 16 sessions. ?	↓ Ferritin ↓ d-dimer in 24/48 h ↑ Clinic. Am J Case Rep. 2020 Aug 17;21:e925849
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta NCT04444531	18 participants. Ozone autohemotherapy plus standard treatment	International Immunopharmacology 2020 December 5, 90: 107261
TURKEY Prevention Sponsor: Marmara University // NCT04400006	10 session in 6 months MAH O ₂ /O ₃ : Blood 1:1 100 mL O ₃ 10 -20 µg/mL.71 participants.	Completed recruitment No Results Posted

Legend: E.C., etic committee; S.E. side effects; IRB, Institutional Review Boards; FIO; New Italian Federation of Ozone Therapy; O₃SS, ozonized Saline Solution; MAH, Mayor autohemotherapy; EBOO, Extracorporeal blood oxygenation-ozonation; RIO3, rectal insufflation; SIOOT, Società Scientifica Ossigeno Ozono Terapia; AIRO, Accademia Internazionale di Ricerca in Ossigeno-Ozono Terapia. * No more patients available, author will write a case report; ? Not confirmation available.